Loading stock data…
IQVIA Holdings Inc. provides clinical research services (IQV)
$208.05+0.73 (+0.35%)
After Hours$208.05+0.00 (+0.00%)· Last close Jul 24
IQVIA Holdings Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IQVIA Holdings Inc. in the Healthcare sector is trading at $208.05 with a market capitalization of $29.7B. Wall Street consensus targets $232.00 (19 analysts), implying a +11.5% move over the next 12 months. The stock is currently 16% below its 52-week high of $247.05, remaining 5.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +11.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $4.15B↓ | $4.36B↑ | $4.10B↑ | $4.02B↑ | $3.83B |
| Gross Profit | $1.35B↓ | $1.44B↑ | $1.37B↑ | $1.32B↑ | $1.30B |
| Operating Income | $565.00M↓ | $651.00M↑ | $573.00M↑ | $538.00M↑ | $525.00M |
| Net Income | $274.00M↓ | $514.00M↑ | $331.00M↑ | $266.00M↑ | $249.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Techno...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$29.71B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
22.26%
Volume
Today's trading volume
888,085
Recent News
IQVIA Gears Up to Report Q2 Earnings: What's in the Offing?
IQV heads into its Q2'26 earnings release with y/y revenue and EPS growth expected, supported by AI adoption, drug launches and high-margin segment gains.
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
Veracyte (VCYT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA Holdings (IQV) Reports Next Week: Wall Street Expects Earnings Growth
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQV vs. PEN: Which Stock Is the Better Value Option?
IQV vs. PEN: Which Stock Is the Better Value Option?
1 Cash-Producing Stock to Target This Week and 2 We Question
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.